TRYVIO/JERAYGO (aprocitentan)
Resistant Hypertension
MarketedCommercial
Key Facts
About Idorsia
Idorsia's mission is to discover, develop, and commercialize innovative medicines, building on a legacy of scientific excellence from its Actelion origins. Its key achievement is the global commercialization of QUVIVIQ (daridorexant), a dual orexin receptor antagonist for insomnia, alongside the recent approval of TRYVIO/JERAYGO (aprocitentan) for resistant hypertension. The company's strategy is centered on unlocking the full value of its commercial assets, expanding strategic partnerships, advancing a prioritized pipeline, and maintaining financial discipline, all supported by a highly skilled team of approximately 500 employees.
View full company profileOther Resistant Hypertension Drugs
| Drug | Company | Phase |
|---|---|---|
| Barostim™ | CVRx | CE Mark |
| DirectAblate Renal Denervation System | Symple Surgical | Pre-clinical |
| Firibastat | Quantum Genomics | Phase IIb/III |
| Aprocitentan | Johnson & Johnson | Approved |
| Baxdrostat | AstraZeneca | Phase III |